Drug Trial Radar · NCT05794191
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350,399
Actual
Start
Mar 22, 2023
Primary completion
Aug 15, 2024
Study completion Aug 15, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.
Conditions
- HIV
- Pneumonia
- Infections, Pneumococcal
Interventions
Vaccine AdministrationBiological
PCV13 administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
- VE for First Event of IPD at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
- VE for First Event of IPD at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
- VE for First Event of IPD at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up
- PCV13 VE for First Event of Pneumococcal Pneumonia (PP): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
- VE for First Event of PP at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
- VE for First Event of PP at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
- VE for First Event of PP at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up
- PCV13 VE for First Event of All-cause Pneumonia (ACP): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
- VE for First Event of ACP at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
- VE for First Event of ACP at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
- VE for First Event of ACP at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.